Tardive Dyskinesia
(TD)
Definition
- Abnormal twisting movements
- Abnormal postures due to sustained muscle contractions
Causes
Risk Factors
-
Use of neuroleptic drugs, especially if the drugs:
- Are taken in high doses and longer than six months
- Are first generation drugs
- Use of metoclopramide and prochlorperazine—These medicines are used to treat gastrointestinal problems, like nausea, vomiting, delayed bowel emptying, and gastroesophageal reflux disease (GERD), especially if taken more than three months.
- Age: 54 or older
- Sex: female
- Possible genetic factor
-
Having a disease that may require using neuroleptic drugs, such as:
- Mood disorders or other psychiatric disorders
- Behavior problems that occur with psychiatric or neurologic disorders, such as agitation in Alzheimer’s disease
-
Digestive disorders such as:
- Esophageal reflux
- Nausea and vomiting
- Diabetes —Diabetic gastroparesis may require the medicine metoclopramide.
- Parkinsonism caused by neuroleptic drugs
Symptoms
- Stress
- Moving other parts of the body
- Taking certain drugs
- Relaxation
- Sleep
- Purposely moving the affected body part
- Grimacing
- Sticking out the tongue
- Twisting the tongue
- Chewing
- Sucking
- Smacking lips
- Puckering lips
- Blinking eyes
- Facial tics
- Foot tapping
- Moving fingers as if playing the piano
- Rapidly moving arms, legs, or body
- Writhing movements
- Pelvic thrusts
- Grunting
- Sighing
- Noisy breathing
Diagnosis
- Your bodily fluids may be tested. This can be done with blood tests.
- Pictures may be taken of structures inside your head. This can be done with:
| CT Scan of the Head |
|
| Copyright © Nucleus Medical Media, Inc. |
Treatment
- Stop the neuroleptic medicine
- Lower the dose
- Switch you to a different medicine, such as an atypical antipsychotic
- Recommend vitamin B6 or vitamin E to reduce the risk of worsening symptoms—These vitamins are still being studied.
Medication
- Melatonin
- Trihexyphenidyl
- Reserpine
- Propranolol
- Clonidine
- Baclofen
-
Sedatives, such as:
- Diazepam
- Clonazepam
-
Antiseizure drugs, such as:
- Valproic acid
- Levetiracetam
- Antipsychotic drugs that may help with movement disorders, such as sulpiride, oxypertine, tiapride and other medicines, such as L-dopa, which is a type of amino acid.
- Diphenhydramine
Surgery
Prevention
-
Talk with your doctor about:
- Risks and benefits of the medicine
- Whether the dose is right for you and how well the drug is working
- Other medicines you can try that have less risk of TD
- Whether you can take a drug holiday, to take a break from using the medicine
- Even a small symptom of TD that you have—Early treatment works best.
- Do not stop taking your medicine without first talking to your doctor. If you stop the drug right away, it may trigger TD.
- See your doctor every three months.
RESOURCES
National Alliance on Mental Illness http://www.nami.org
National Institute of Neurological Disorders and Stroke http://www.ninds.nih.gov
CANADIAN RESOURCES
Canadian Mental Health Association http://www.ontario.cmha.ca
Mental Health Canada http://www.mentalhealthcanada.com
References
Bai YM, Yu SC, Lin CC. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry . 2003;64:1342-1348.
Bradley WG, Daroff RB, Fenichel G, Jankovic J. Neurology in Clinical Practice. 4th ed. Butterworth Heinemann; 2003. Accessed November 4, 2007.
Cecil RL, Goldman L, Bennett JC. Cecil Textbook of Medicine . 21st ed. Philadelphia, PA: WB Saunders Co; 2000.
Conn HF, Rakel RE. Conn's Current Therapy 2001 . 53rd ed. Philadelphia, PA: WB Saunders Co; 2001.
Dambro M. Griffith's 5-Minute Clinical Consult . Baltimore, MD: Lippincott Williams & Wilkins; 2001.
Damier P. Drug-induced dyskinesias. Curr Opin Neurol . 2009;22(4):394-399.
Goroll A, Mulley A. Primary Care Medicine . 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000.
Kinon BJ, Jeste DV, Kollack-Walker S, Stauffer V, Liu-Seifert H. Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods. Prog Neuropsychopharmacol Biol Psychiatry . 2004;28:985-996.
McGrath JJ, Soares KV. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Database Syst Rev . 2006;CD000459.
Meco G, Fabrizio E, Epifanio A, et al. Levetiracetam in tardive dyskinesia. Clin Neuropharmacol . 2006;29:265-268.
Noble J, Greene HL. Textbook of Primary Care Medicine . 3rd ed. St. Louis, MO: Mosby Inc; 2001.
Pham DQ, Plakogiannis R. Vitamin E supplementation in Alzheimer’s disease, Parkinson’s disease, tardive dyskinesia, and cataract: part 2. Ann Pharmacother . 2005;39(12):2065-72.
Sachdev PS. The current status of tardive dyskinesia. Australian and New Zealand Journal of Psychiatry . 2000;34:355-369.
Soares KV, McGrath JJ. The treatment of tardive dyskinesia: a systematic review and meta-analysis. Izophr Res. 1999;39(1):1-16.
Tardive dyskinesia. EBSCO DynaMed website. Available at: http://www.ebscohost.com/dynamed/ . Updated November 23, 2011. Accessed February 25, 2013.
Tardive dyskinesia. National Alliance on Mental Illness website. Available at: http://www.nami.org/Content/ContentGroups/Helpline1/Tardive%5FDyskinesia.htm . Updated September 2003. Accessed February 25, 2013.
Tasman A, Kay J, Lieberman J. Psychiatry . Philadelphia, PA: WB Saunders Co; 1997.
Thema B, Srivastava V, Tiwari AK. Genetic underpinnings of tardive dyskinesias: passing the baton to pharmacogenetics. Pharmacogenomics. 2008;9:1285-1306.

